News
2d
Clinical Trials Arena on MSNAssembly Bio’s herpes drug shows 94% drop in viral shedding
Assembly Biosciences is advancing its herpes drug to Phase II trials after it showed 94% antiviral efficacy in a Phase Ib ...
Growing research shows common herpes viruses may raise dementia risk, challenging previous skepticism and opening new paths ...
It’s estimated that, globally, around 67% of people under 50 have herpes simplex virus type 1 (HSV-1) infection, the main cause of oral herpes or cold sores, and around 13% have herpes simplex ...
Inferred father-to-son transmission of herpes simplex virus results in near-perfect preservation of viral genome identity and in vivo phenotypes. Scientific Reports, 2017; 7 (1) DOI: 10.1038 ...
These asymptomatic herpes carriers shed infectious virus 10 percent of the 30 or more days they were in the study, report University of Washington researcher Anna Wald, MD, MPH, and colleagues.
Many adults are infected with herpes simplex virus type 1 (HSV-1), a lifelong condition that often manifests as annoying cold sores but has the potential, albeit rare, to lead to more serious ...
It may present as blisters on the chest, neck, and face. Once the herpes simplex virus 1 (HSV-1) enters the body, it resides there for life.
So once someone gets infected, they've got the virus for life. In the 15-to-49-year-old age range, 1 in 5 people are living with a genital herpes infection — that's about 846 million people.
Herpes simplex virus or HSV is a virus that can appear in various parts of the body, most commonly the genitals or mouth. Once we have the virus inside of us, we can’t get rid of it on our own.
In a Facebook post that has received 3,000 likes and 1,200 comments, Rhian Brace — a mom in Doncaster, England — discussed her son Ernie’s struggle with Herpes simplex virus.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results